Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement Bill Increasing FDA Access To Safety Data Planned By Waxman

This article was originally published in The Tan Sheet

Executive Summary

Reps. Henry Waxman (D-Calif.) and Susan Davis (D-Calif.) are working on legislation "that will give FDA greater access to information to understand if a [dietary supplement] product does pose a health risk and will let FDA protect consumers from unsafe products," Waxman said at a July 23 hearing of the House Energy & Commerce/Oversight & Investigations Subcommittee

You may also be interested in...



Mandatory AER sponsor in House?

Rep. Greg Walden (R-Ore.) is expected to assume the chairmanship of the Energy & Commerce/Oversight & Investigations Subcommittee with Rep. James Greenwood's (R-Penn.) decision to become president of the Biotechnology Industry Organization. Greenwood will finish his term before joining BIO Jan. 5, but has resigned his post as subcommittee chair. Walden's leadership could provide a forum in the House for debating mandatory adverse event reporting for supplements, an issue soon to be tackled in the higher chamber by Sens. Richard Durbin (D-Ill.) and Orrin Hatch (R-Utah) (1"The Tan Sheet" June 28, 2004, p. 3). Walden has expressed support for mandatory reporting in the past (2"The Tan Sheet" July 28, 2003, p. 3). The Oregonian Republican also spearheaded efforts to ban ephedra, including sponsorship of a related bill in March 2003 and a subpoena of Metabolife execs...

Mandatory AER sponsor in House?

Rep. Greg Walden (R-Ore.) is expected to assume the chairmanship of the Energy & Commerce/Oversight & Investigations Subcommittee with Rep. James Greenwood's (R-Penn.) decision to become president of the Biotechnology Industry Organization. Greenwood will finish his term before joining BIO Jan. 5, but has resigned his post as subcommittee chair. Walden's leadership could provide a forum in the House for debating mandatory adverse event reporting for supplements, an issue soon to be tackled in the higher chamber by Sens. Richard Durbin (D-Ill.) and Orrin Hatch (R-Utah) (1"The Tan Sheet" June 28, 2004, p. 3). Walden has expressed support for mandatory reporting in the past (2"The Tan Sheet" July 28, 2003, p. 3). The Oregonian Republican also spearheaded efforts to ban ephedra, including sponsorship of a related bill in March 2003 and a subpoena of Metabolife execs...

Mandatory AER sponsor in House?

Rep. Greg Walden (R-Ore.) is expected to assume the chairmanship of the Energy & Commerce/Oversight & Investigations Subcommittee with Rep. James Greenwood's (R-Penn.) decision to become president of the Biotechnology Industry Organization. Greenwood will finish his term before joining BIO Jan. 5, but has resigned his post as subcommittee chair. Walden's leadership could provide a forum in the House for debating mandatory adverse event reporting for supplements, an issue soon to be tackled in the higher chamber by Sens. Richard Durbin (D-Ill.) and Orrin Hatch (R-Utah) (1"The Tan Sheet" June 28, 2004, p. 3). Walden has expressed support for mandatory reporting in the past (2"The Tan Sheet" July 28, 2003, p. 3). The Oregonian Republican also spearheaded efforts to ban ephedra, including sponsorship of a related bill in March 2003 and a subpoena of Metabolife execs...

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095752

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel